Introduction
============

Gastric cancer is one of the most common cancers world-wide, especially in Asia [@b1]. There is accumulating evidence that aberrant DNA methylation is a hallmark of gastric cancer [@b2]. The identification of novel tumour suppressor genes repressed by DNA methylation will provide us with insights into the functional roles in gastric carcinogenesis and will be useful in discovering potential biomarkers [@b3],[@b4].

We used methylated DNA immunoprecipitation-chip (MeDIP-chip) to identify the novel methylated genes on a genome-wide scale [@b5]. The principle of MeDIP-chip is the use of an antibody specific for methylcytosine to immunoprecipitation of methylated DNA for downstream applications. Promoter methylated genes are determined and compared between cancer cell lines and normal tissues. From our preliminary data, we discovered that the promoter of the *odd-skipped related 1* (*OSR1*) gene was preferentially methylated in gastric cancer cell lines. The *OSR1* gene is located on human chromosome 2p24.1 encoding a zinc-finger transcription factor [@b6]. *OSR1* plays important roles in the development of intermediate mesoderm, and it is also essential for embryonic heart and urogenital formation [@b7]--[@b9]. Although the role of *OSR1* in cancer development is unknown, hypermethylated CpG islands associated with *OSR1* have been reported in lung cancer [@b10]. This suggests that *OSR1* has some kind of function in cancer development.

It is known that the Wnt/β-catenin pathway and p53 pathway play important roles in gastric carcinogenesis [@b11]--[@b13]. In the Wnt/β-catenin canonical pathway, Wnt ligands bind to the transmembrane receptors Frizzled and lipoprotein receptor-related protein (LRP) 5 and 6, which leads to the accumulation of β-catenin in the cytoplasm [@b14],[@b15]. The accumulated β-catenin is translocated from cytoplasm to the nucleus, where it forms a complex with T-cell factor (TCF)/lymphoid enhancer factor (LEF) to mediate the transcription of target genes [@b16]--[@b18]. The Wnt/β-catenin canonical pathway becomes an oncogenic pathway in cancer development. On the other hand, p53 is a known tumour suppressor and activates the transcription of the downstream target genes involved in cell cycle arrest and apoptosis [@b19],[@b20]. Notably, Huang suggested that *OSR1* was one of the agonists of the p53 network by genome-wide functional analysis [@b21]. In the present study, we have investigated the expression and promoter methylation profile of *OSR1*.

Materials and methods
=====================

Cell lines
----------

The gastric cancer cell lines (AGS, MKN28, MKN45, SNU1, SNU16, SNU638, SNU719, MGC803, and NCI-N87) and immortalized normal human gastric epithelial cell line (GES1) were purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA) and the Cancer Research Institute of Beijing University, China. The cell lines were cultured in RPMI-1640 medium (Gibco; Life Technologies, Carlsbad, CA, USA) with 10% fetal bovine serum (FBS) in 5% CO~2~ at 37 °C.

The colon cancer cell line HCT116 p53-wild type cells were purchased from ATCC and HCT116 p53-knockout cells were kindly provided by Professor Bert Vogelstein from the Ludwig Center and the Howard Hughes Medical Institute at the Johns Hopkins University School of Medicine. HCT116 p53-wild type cells were cultured in McCoy\'s 5A medium (Sigma-Aldrich, St Louis, MO, USA) with 10% FBS and HCT116 p53-knockout cells were cultured in Dulbecco\'s modified Eagle\'s medium (Gibco; Life Technologies) with 10% FBS in 5% CO~2~ at 37 °C.

Gastric tissue samples
----------------------

Paired biopsy tissues from primary gastric cancer and adjacent normal mucosa were obtained during endoscopy at the Prince of Wales Hospital of the Chinese University of Hong Kong. Primary gastric cancer tissues were collected during operation from gastric cancer patients diagnosed at the First Affiliated Hospital of Sun Yat-sen University in Guangzhou, China. In addition, age-matched biopsy specimens of normal gastric mucosa were obtained as controls. Written consent was obtained prior to sample collection, and the study protocol was approved by the Clinical Research Ethics Committee of the Chinese University of Hong Kong and the Sun Yat-sen University of Medical Sciences.

Genome-wide profiling by MeDIP-chip
-----------------------------------

We determined the DNA methylation profile of gastric cancer cells by MeDIP-chip using the Agilent Custom Human CpG Island Microarray and Human Promoter Array (Agilent Technologies, Santa Clara, CA, USA) as reported previously [@b5].

Semi-quantitative reverse transcriptase-PCR and quantitative real-time PCR analyses
-----------------------------------------------------------------------------------

Semi-quantitative reverse transcriptase (RT)-PCR was performed by Go-Taq DNA polymerase (Promega, Madison, WI, USA). Quantitative real-time PCR was performed by SYBR Green PCR Master Mix (Applied Biosystems; Life Technologies) on a 7500HT Fast Real-Time PCR System (Applied Biosystems; Life Technologies). The primer sequences are listed in Supplementary Table 1.

Treatment with 5-aza-2\'-deoxycytidine and trichostatin A
---------------------------------------------------------

After 24 h of cell seeding, cells were treated with 2 µ[m]{.smallcaps} of the demethylating agent 5-aza-2\'-deoxycytidine (5-Aza; Sigma-Aldrich) for 96 h. Some cell lines were further treated with 300 n[m]{.smallcaps} of the histone deacetylase inhibitor trichostatin A (TSA) for an additional 24 h.

Methylation-specific PCR and bisulphite genomic sequencing
----------------------------------------------------------

Methylation-specific PCR (MSP) and bisulphite genomic sequencing (BGS) were performed to amplify the bisulphite-modified DNA by TaKaRa Taq HS (TaKaRa, Ohtsu, Japan). The MSP region was selected from −19 to +83 bp of the transcription start site (TSS) and the BGS region was selected from −55 to +202 bp of the TSS ([Figure 1](#fig01){ref-type="fig"}D). Primer sequences for MSP and BGS are listed in Supplementary Table 1. PCR products of BGS were submitted to the Research Center of BGI, Hong Kong for sequencing. The methylation percentage of each CpG site was calculated according to the formula methylation % = *H*~C~/(*H*~C~ + *H*~T~) × 100% (*H*~C~ = height of peak C and *H*~T~ = height of peak T).

![*OSR1* is silenced or down-regulated by promoter methylation in gastric cancer cells. (A) Expression of *OSR1* mRNA in human organ tissues was determined by semi-quantitative reverse transcriptase (RT)-PCR. (B1) Expression of *OSR1* mRNA in gastric cancer cell lines and normal gastric epithelial cell line. (B2) Expression of OSR1 protein in gastric cancer cell lines and normal gastric epithelial cell line. (C1) Treatment with the demethylating agent 5-aza-2\'-deoxycytidine (5-Aza) restored *OSR1* expression in gastric cancer cell lines. (C2) Combination treatment with 5-Aza and the histone deacetylase inhibitor trichostatin A (TSA) restored *OSR1* expression in MKN45 and SNU16. (D) A typical CpG island spans the promoter region of *OSR1*. The transcription start site (TSS) and the regions of bisulphite genomic sequencing (BGS) and methylation-specific PCR (MSP) are indicated. Methylation status of *OSR1* in the gastric cancer cell lines was determined by BGS and MSP (M, methylated; U, unmethylated).](path0234-0302-f1){#fig01}

Immunohistochemistry
--------------------

Immunohistochemistry was performed by Histostain-*Plus* Kits (Broad Spectrum) and an Invitrogen 2nd Generation LAB-SA Detection System (Invitrogen; Life Technologies). Slides were incubated with a primary antibody to OSR1 (ab74003; Abcam, Cambridge, MA, USA) followed by a biotinylated secondary antibody and enzyme conjugate, stained with 3,3\'-diaminobenzidine, and finally counterstained with haematoxylin. The extent of OSR1 staining was scored by assigning the percentage of positive tumour cells (0, none; 1, \< 20% of positive staining cells; 2, 20--50% of positive staining cells; 3, \> 50% of positive staining cells).

Western blotting
----------------

Protein blots were detected with primary antibodies to OSR1 (sc-376545; Santa Cruz Biotechnology, Santa Cruz, CA, USA), p21 (sc-6246; Santa Cruz Biotechnology), cyclin D1 (sc-8396; Santa Cruz Biotechnology), cyclin-dependent kinase 4 (CDK4; \#2906; Cell Signaling Technology, Danvers, MA, USA), Fas (\#4233; Cell Signaling Technology), cleaved caspase-3 (\#9661; Cell Signaling Technology), cleaved poly-(ADP-ribose) polymerase (PARP; \#5625; Cell Signaling Technology), cyclin B1 (sc-245; Santa Cruz Biotechnology), followed by a secondary antibody, and developed with enhanced chemiluminescence (Amersham, Arlington Heights, IL, USA). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH; sc-32233; Santa Cruz Biotechnology) served as a loading control.

Nuclear protein and cytoplasmic protein were extracted by NE-PER Nuclear and Cytoplasmic Extraction Reagents (Pierce; Thermo Fisher Scientific, Rockford, IL, USA). Nuclear protein was detected with p53 (sc-126; Santa Cruz Biotechnology) antibody and lamin A/C (612162; BD Biosciences, San José, CA, USA) was used as a loading control. Cytoplasmic protein was detected with β-catenin (\#9582; Cell Signaling Technology) antibody and actin (sc-1615; Santa Cruz Biotechnology) was used as a loading control.

Construction of the *OSR1* expression plasmid
---------------------------------------------

The complete open reading frame of human *OSR1* (NM_145260.2) was amplified by PCR from normal human stomach complementary DNA (cDNA). The inserts were subcloned into pcDNA3.1 (+) expression vector (Invitrogen; Life Technologies) by HindIII and XbaI. The primer sequences are listed in Supplementary Table 1. Plasmid DNA was purified from transformed *E. coli* cultures by a Pure Yield Plasmid Midiprep System (Promega). Cells were transfected with pcDNA3.1-*OSR1* or empty pcDNA3.1 by Lipofectamine 2000 (Invitrogen; Life Technologies).

*OSR1* knockdown
----------------

Cells were transfected with short hairpin RNA (shRNA) pGFP-V-RS-sh*OSR1* (TG302745, Origene) or shRNA control vector by Lipofectamine 2000.

Cell viability, colony formation, and cell proliferation assay
--------------------------------------------------------------

After 48 h of transfection, cells were cultured in the medium with G418 (Roche Applied Science, Mannheim, Germany) for pcDNA3.1 or puromycin (Gibco; Life Technologies) for the shRNA vector. After 14 days of selection to establish stable clones, cells were seeded for 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H-tetrazolium (MTS; Promega) assay to measure the cell viability and colony formation assay counting the colonies (≥50 cells per colony) after staining with 5% crystal violet. Cell proliferation was monitored by the xCELLigence system (Roche Applied Science).

Cell cycle assay
----------------

Stably transfected cells were fixed in 70% ethanol and stained with PI/RNase Staining Buffer (BD Biosciences). The cells were sorted by a fluorescence activated cell sorting (FACS) Calibur system (BD Biosciences) and analysed by ModFit 3.0 software (Verity Software House, Topsham, ME, USA).

Apoptosis assay
---------------

Stably transfected cells were stained with annexin V-APC (BD Biosciences) and 7-aminoactinomycin (7-AAD). The cells were sorted by a FACS Calibur system and annexin V-positive cells were counted as apoptotic cells.

Dual-luciferase reporter assay
------------------------------

Stably transfected cells in a 24-well plate were co-transfected with luciferase reporter plasmid (p53-Luc or TOPflash; 200 ng/well) and pRL-cytomegalovirus vector (5 ng/well) by Lipofectamine 2000. After 48 h of transfection, luciferase activities were analysed by a Dual-Luciferase Reporter Assay System (Promega) and normalized to the control *Renilla*.

Mutational analysis of β-catenin
--------------------------------

Genomic DNA was extracted using PureLink Genomic DNA Kits (Invitrogen; Life Technologies) and amplified by PCR using TaKaRa Ex Taq (TaKaRa). β-Catenin is encoded by the *CTNNB1* gene in humans [@b22]. We examined exon 3 of *CTNNB1* using the primers previously reported by Sasaki [@b23]. PCR products of BGS were submitted to the Research Center of BGI, Hong Kong for sequencing.

cDNA expression array
---------------------

Gene expression profiles in stably transfected cells were analysed by the Human p53 Signaling Pathway RT^2^ Profiler PCR Array (PAHS-027Z; Qiagen, Hilden, Germany) and the Human Wnt Signaling Pathway RT^2^ Profiler PCR Array (PAHS-043Z; Qiagen). Gene expression changes ≥ 1.5-fold or ≤ 0.67-fold were considered to be of biological significance.

Genome-wide DNA methylation and microsatellite instability analyses
-------------------------------------------------------------------

Genome-wide DNA methylation status in 43 gastric cancer tissues was detected by a 5-mC DNA ELISA Kit (Zymo Research, Irvine, CA, USA). Microsatellite instability (MSI) was examined by an MSI Analysis System, Version 1.2 (Promega).

Statistics
----------

Values are expressed as mean ± standard deviation (SD). The independent Student *t*-test was used to compare the difference between two groups. One-way analysis of variance (ANOVA) was used to compare the difference between multiple groups, and the results were analysed by Tukey\'s multiple comparisons test. The χ^2^ test was used to compare the clinicopathological characteristics of gastric cancer patients and *OSR1* methylation. Univariate and multivariate Cox regression analyses were performed to assess the prognostic value of *OSR1* methylation. Overall survival in relation to methylation status was evaluated by Kaplan--Meier survival curve and log-rank test. Differences with *p* \< 0.05 were considered to be statistically significant.

Results
=======

*OSR1* expression is epigenetically down-regulated in gastric cancer cells
--------------------------------------------------------------------------

We examined the expression of *OSR1* mRNA through semi-quantitative RT-PCR. In human normal tissues including normal gastric tissue, expression of *OSR1* mRNA was broadly detected ([Figure 1](#fig01){ref-type="fig"}A). In contrast, expression of *OSR1* mRNA was silenced or down-regulated in most of the gastric cancer cells, and high expression of *OSR1* mRNA was found in the normal gastric epithelial cell line GES1 ([Figure 1](#fig01){ref-type="fig"}B1). In keeping with the mRNA expression, silence or down-regulation of OSR1 protein in gastric cancer cell lines was demonstrated by western blotting ([Figure 1](#fig01){ref-type="fig"}B2). To confirm whether *OSR1* expression was repressed by promoter methylation, the demethylating agent 5-Aza was employed. The results showed that 5-Aza treatment could restore *OSR1* expression in AGS, MKN28, SNU719, and MGC803 ([Figure 1](#fig01){ref-type="fig"}C1). Although the restoration of *OSR1* by 5-Aza was insufficient in MKN45 and SNU16, combination treatment with 5-Aza and the histone deacetylase inhibitor TSA markedly restored *OSR1* expression ([Figure 1](#fig01){ref-type="fig"}C2).

The methylation status of *OSR1* was further evaluated by BGS and MSP analysis. Full methylation was detected in AGS, MKN28, and MGC803, and partial methylation was found in SNU638 and NCI-N87. No methylation was detected in MKN45, SNU1, SNU16, and GES1. The MSP results were confirmed to be consistent with the BGS results ([Figure 1](#fig01){ref-type="fig"}D).

*OSR1* expression is down-regulated in primary gastric cancer tissues
---------------------------------------------------------------------

Expression of *OSR1* mRNA in paired primary gastric cancer tissues was evaluated by quantitative real-time PCR. The expression levels of *OSR1* mRNA were significantly down-regulated by 0.39-fold in 20 gastric cancers compared with adjacent normal tissues (*p* \< 0.01; [Figure 2](#fig02){ref-type="fig"}A).

![*OSR1* is down-regulated in primary gastric cancer tissues. (A) Expression levels of *OSR1* mRNA in 20 paired primary gastric cancer tissues were determined by quantitative real-time PCR. (B) Expression levels of OSR1 protein in seven paired primary gastric cancer tissues were determined by western blotting. Quantitative analysis of the relative expression density is shown in the lower panel. Each column represents the mean ± standard deviation (SD). ^\*\*^*p* \< 0.01 (N, normal; C, cancer). (C1) Expression levels of OSR1 protein in 13 paired primary gastric cancer tissues were determined by immunohistochemistry. Expression of OSR1 protein in normal gastric tissues and gastric cancer tissues is shown. The lower three images indicate cancer cell infiltration under the adjacent normal epithelial mucosa. (C2) Immunohistochemistry scoring was performed according to the percentage of positive tumour cells (0, none; 1, \< 20%; 2, 20--50%; 3, \> 50%). Each bar represents the mean ± SD.](path0234-0302-f2){#fig02}

Expression of OSR1 protein in paired gastric cancer tissues was further examined by western blotting. The expression levels of OSR1 protein were significantly down-regulated by 0.44-fold in seven gastric cancers compared with adjacent normal tissues (*p* \< 0.01; [Figure 2](#fig02){ref-type="fig"}B). Expression of OSR1 protein was also evaluated by immunohistochemical analysis. OSR1 protein was strongly expressed in both the nucleus and the cytoplasm in adjacent normal tissues. However, OSR1 signal was much reduced in primary gastric cancer tissues ([Figure 2](#fig02){ref-type="fig"}C1). To quantify the extent of OSR1 staining, we scored the rate of positive tumour cells. The results showed that the expression levels of OSR1 protein were significantly down-regulated by 0.35-fold in 13 gastric cancers compared with adjacent normal tissues (*p* \< 0.01; [Figure 2](#fig02){ref-type="fig"}C2).

*OSR1* inhibits cell growth
---------------------------

We examined the effect of *OSR1* overexpression on cell growth in AGS, MKN28, and MGC803, which showed complete methylation and silencing of *OSR1*. Re-expression of *OSR1* mRNA and protein was confirmed by semi-quantitative RT-PCR ([Figure 3](#fig03){ref-type="fig"}A1) and western blotting ([Figure 3](#fig03){ref-type="fig"}A2). Ectopic expression of *OSR1* significantly inhibited cell viability to 74.8% in AGS (*p* \< 0.01), 70.4% in MKN28 (*p* \< 0.01), and 64.1% in MGC803 (*p* \< 0.01), as revealed by MTS assay compared with empty pcDNA3.1 ([Figure 3](#fig03){ref-type="fig"}B). The colony numbers of *OSR1*-transfected cells were significantly decreased to 49.4% in AGS (*p* \< 0.01), 64.0% in MKN28 (*p* \< 0.01), and 63.1% in MGC803 (*p* \< 0.01) by colony formation assay compared with empty pcDNA3.1-transfected cells ([Figures 3](#fig03){ref-type="fig"}C1 and [3](#fig03){ref-type="fig"}C2).

![Overexpression of *OSR1* inhibits cell growth. (A1) Overexpression of *OSR1* mRNA was revealed by semi-quantitative RT-PCR. (A2) Overexpression of OSR1 protein was confirmed by western blotting. (B) Effect of *OSR1* overexpression on cell viability was determined by MTS assay. Each column represents the mean ± SD. ^\*\*^*p* \< 0.01. (C1) Effect of *OSR1* overexpression on colony numbers was determined by colony formation assay. (C2) Quantitative analysis of colony formation efficiency (%) is shown. Each column represents the mean ± SD. ^\*\*^*p* \< 0.01.](path0234-0302-f3){#fig03}

We further investigated the effect of *OSR1* knockdown by *OSR1*-shRNA-1 on cell growth in GES1. Knockdown of *OSR1* was confirmed by semi-quantitative RT-PCR ([Figure 4](#fig04){ref-type="fig"}A1), western blotting ([Figure 4](#fig04){ref-type="fig"}A2), and quantitative real-time PCR (*p* \< 0.01; [Figure 4](#fig04){ref-type="fig"}A3). Knockdown of *OSR1* by *OSR1*-shRNA-1 significantly enhanced cell viability to 119.1% (*p* \< 0.01; [Figure 4](#fig04){ref-type="fig"}B), cell proliferation (*p* \< 0.01; [Figure 4](#fig04){ref-type="fig"}C), and colony numbers to 137.7% (*p* \< 0.01; [Figure 4](#fig04){ref-type="fig"}D). We validated the results of the knockdown assays using *OSR1*-shRNA-2 ([Figures 4](#fig04){ref-type="fig"}E--[4](#fig04){ref-type="fig"}G).

![Knockdown of *OSR1* by *OSR1*-shRNA-1 (A--D) and *OSR1*-shRNA-2 (E--G) enhances cell growth. (A1) Knockdown of *OSR1* mRNA was revealed by semi-quantitative RT-PCR (shCt, shRNA control vector; sh*OSR1*-1, *OSR1*-shRNA-1). (A2) Knockdown of OSR1 protein was confirmed by western blotting. (A3) Knockdown efficiency of *OSR1* mRNA was examined by quantitative real-time PCR. Each column represents the mean ± SD. ^\*\*^*p* \< 0.01. (B) Effect of *OSR1* knockdown on cell viability was determined by MTS assay. Each column represents the mean ± SD. ^\*\*^*p* \< 0.01. (C) Effect of *OSR1* knockdown on cell proliferation was determined by xCELLigence analysis. Data are shown as mean ± SD. (D) Effect of *OSR1* knockdown on colony numbers was determined by colony formation assay. Quantitative analysis of colony formation efficiency (%) is shown in the right panel. Each column represents the mean ± SD. ^\*\*^*p* \< 0.01. (E1) Knockdown of *OSR1* mRNA was revealed by semi-quantitative RT-PCR (shCt, shRNA control vector; sh*OSR1*-2, *OSR1*-shRNA-2). (E2) Knockdown of OSR1 protein was confirmed by western blotting. (E3) Knockdown efficiency of *OSR1* mRNA was examined by quantitative real-time PCR. Each column represents the mean ± SD. ^\*\*^*p* \< 0.01. (F) Effect of *OSR1* knockdown on cell viability was determined by MTS assay. Each column represents the mean ± SD. ^\*\*^*p* \< 0.01. (G) Effect of *OSR1* knockdown on colony numbers was determined by colony formation assay. Quantitative analysis of colony formation efficiency (%) is shown in the right panel. Each column represents the mean ± SD. ^\*\*^*p* \< 0.01.](path0234-0302-f4){#fig04}

*OSR1* induces cell cycle arrest
--------------------------------

Overexpression of *OSR1* significantly increased cells at the G~1~ phase (57.7 ± 1.1% versus 68.2 ± 1.1%, *p* \< 0.01) and decreased cells at the S phase (27.4 ± 0.18% versus 18.7 ± 1.2%, *p* \< 0.01) in AGS. On the other hand, overexpression of *OSR1* significantly reduced cells at the S phase (24.6 ± 0.78% versus 11.8 ± 0.48%, *p* \< 0.01) and elevated cells at the G~2~ phase (48.2 ± 1.1% versus 73.1 ± 0.60%, *p* \< 0.01) in MKN28. Overexpression of *OSR1* also significantly decreased cells at the S phase (36.3 ± 0.94% versus 33.1 ± 0.84%, *p* \< 0.05) and increased cells at the G~2~ phase (14.9 ± 1.6% versus 20.3 ± 0.86%, *p* \< 0.01) in MGC803. Knockdown of *OSR1* by *OSR1*-shRNA-1 and *OSR1*-shRNA-2 significantly decreased cells at the G~1~ phase (57.6 ± 1.3% versus 48.3 ± 1.3%, *p* \< 0.01; 55.6 ± 1.5% versus 46.5 ± 1.2%, *p* \< 0.01) and increased cells at the S phase (35.8 ± 0.91% versus 42.7 ± 2.1%, *p* \< 0.01; 36.3 ± 0.91% versus 41.6 ± 2.4%, *p* \< 0.01) in GES1 ([Figure 5](#fig05){ref-type="fig"}A).

![*OSR1* arrests the cell cycle and induces apoptosis. (A) Effects of *OSR1* overexpression and knockdown on the cell cycle were determined by fluorescence activated cell sorting (FACS) analysis. Quantitative analysis of cell proportion (%) is shown in the right panel. Each column represents the mean ± SD. ^\*^*p* \< 0.05; ^\*\*^*p* \< 0.01 (shCt, shRNA control vector; sh*OSR1*-1, *OSR1*-shRNA-1; sh*OSR1*-2, *OSR1*-shRNA-2). (B) Effects of *OSR1* overexpression and knockdown on apoptosis were determined by FACS analysis after the dual staining with annexin V-APC and 7-aminoactinomycin (7-AAD). Quantitative analysis of apoptotic cells (%) is shown in the right panel. Each column represents the mean ± SD. ^\*^*p* \< 0.05; ^\*\*^*p* \< 0.01.](path0234-0302-f5){#fig05}

*OSR1* induces apoptosis
------------------------

Overexpression of *OSR1* significantly increased the numbers of apoptotic cells in AGS (11.2 ± 3.3% versus 19.1 ± 2.5%, *p* \< 0.05), MKN28 (7.1 ± 1.1% versus 12.2 ± 1.6%, *p* \< 0.05), and MGC803 (15.6 ± 1.3% versus 19.6 ± 1.8%, *p* \< 0.05). Knockdown of *OSR1* in GES1 by *OSR1*-shRNA-1 (40.5 ± 3.4% versus 25.8 ± 2.8%, *p* \< 0.01) and *OSR1*-shRNA-2 (46.7 ± 4.9% versus 24.4 ± 2.6%, *p* \< 0.01) significantly decreased the numbers of apoptotic cells ([Figure 5](#fig05){ref-type="fig"}B).

*OSR1* activates p53 transcription and represses TCF transcription
------------------------------------------------------------------

To clarify the tumour suppressive pathways modulated by *OSR1*, we measured p53 luciferase reporter activity. Overexpression of *OSR1* significantly increased p53 activity by 1.5-fold in AGS (*p* \< 0.01) and 1.7-fold in MKN45 (*p* \< 0.01). Conversely, knockdown of *OSR1* by *OSR1*-shRNA significantly repressed p53 activity by 0.28-fold in GES1 (*p* \< 0.01). In contrast, *OSR1* transfection had no effect on p53 activity in the p53-mutant cell lines MKN28 and MGC803 ([Figure 6](#fig06){ref-type="fig"}A1). In the colon cancer cell line HCT116, overexpression of *OSR1* significantly elevated p53 activity by 2.2-fold in HCT116 p53-wild type cells, but p53 activity could not be detected in HCT116 p53-knockout cells ([Figure 6](#fig06){ref-type="fig"}A2).

![*OSR1* activates the transcription of p53 and represses the transcription of T-cell factor (TCF). (A1) Effect of *OSR1* overexpression and knockdown on p53 luciferase reporter activity was determined in gastric cancer cell lines (WT, wild type; Mut, mutant). Each column represents the mean ± SD. ^\*\*^*p* \< 0.01. (A2) Effect of *OSR1* overexpression on p53 luciferase reporter activity was determined in a colon cancer cell line (WT, wild type; KO, knockout). Each column represents the mean ± SD. ^\*\*^*p* \< 0.01. (A3) Effect of *OSR1* overexpression on TCF luciferase reporter activity was determined in gastric cancer cell lines (WT, wild type; Mut, mutant). Each column represents the mean ± SD. ^\*\*^*p* \< 0.01. (B) Effect of *OSR1* overexpression on the expression levels of candidates in the p53 and Wnt/β-catenin signalling pathway was validated by western blotting. (C) Schematic diagram showing the mechanism of *OSR1* tumour suppressive function.](path0234-0302-f6){#fig06}

TCF luciferase reporter activity was also examined using TOPflash. Overexpression of *OSR1* significantly repressed TCF activity by 0.30-fold in MKN28 (*p* \< 0.01) and 0.31-fold in MGC803 (*p* \< 0.01). In contrast, overexpression of *OSR1* did not affect TCF activity in AGS ([Figure 6](#fig06){ref-type="fig"}A3). In mutation analysis of β-catenin, there were no mutations in MKN28 and MGC803, but there was one mutation at position 88 bp of exon 3 (GGA to GAA) and the protein sequence was also changed (Gly to Glu) in AGS (Supplementary Table 2).

Identification of genes modulated by *OSR1*
-------------------------------------------

We employed the cDNA expression array to examine the molecular mechanism by which *OSR1* exerted tumour suppressive activities. Fold changes of *OSR1*-modulated downstream genes in the p53 signalling pathway were measured in AGS and GES1. Overexpression of *OSR1* significantly increased the expression levels of *CDKN1A* (*p21Cip1*; 3.3-fold), *Fas* (14.2-fold), *death receptor-5* (*DR5*; 3.9-fold), and *Bax* (1.5-fold), and suppressed the expression level of *CDK4* (0.66-fold) in AGS. Conversely, knockdown of *OSR1* significantly reduced the expression levels of *p21Cip1* (0.57-fold), *Fas* (0.66-fold), and *DR5* (0.59-fold), and elevated the expression level of *CDK4* (1.5-fold) in GES1.

Fold changes of *OSR1*-modulated downstream genes in the Wnt/β-catenin signalling pathway were also measured in MKN28 and MGC803. Overexpression of *OSR1* significantly suppressed the levels of *LRP6* (0.41-fold), *CTNNB1* (0.47-fold), *TCF-1* (0.44-fold), *LEF1* (0.46-fold), and *Axis inhibition protein 2* (*Axin2*; 0.36-fold) in MKN28. Overexpression of *OSR1* significantly suppressed the levels of *LRP6* (0.41-fold), *CTNNB1* (0.66-fold), *TCF-1* (0.49-fold), *LEF1* (0.43-fold), and *Axin2* (0.66-fold) in MGC803 (Supplementary Table 3).

The results from the cDNA expression array were validated by western blotting. Overexpression of *OSR1* enhanced the protein expression of p21, Fas, cleaved caspase-3, cleaved PARP, and nuclear p53, and suppressed the protein expression of cyclin D1 and CDK4 in AGS. Overexpression of *OSR1* suppressed the protein expression of cyclin B1 and cytoplasmic β-catenin in MKN28 and MGC803 ([Figure 6](#fig06){ref-type="fig"}B). A schematic diagram for the mechanism of *OSR1* tumour suppressive function derived from the cDNA expression array and western blotting is shown in [Figure 6](#fig06){ref-type="fig"}C.

Clinicopathological features of *OSR1* methylation in gastric cancer patients
-----------------------------------------------------------------------------

We evaluated *OSR1* methylation in 164 primary gastric cancer tissues by BGS. Methylated *OSR1* was detected in 51.8% of primary gastric cancers (85 of 164). We next determined the association between *OSR1* methylation and clinicopathological features such as age, gender, *Helicobacter pylori* infection, Lauren type, differentiation, and tumour--nodes--metastasis (TNM) stage, but no correlations were found (Supplementary Table 4).

In addition, we examined the association of *OSR1* promoter methylation with genome-wide DNA methylation or MSI, respectively. Global DNA hypomethylation was found in 81.4% of gastric cancers (35 of 43), and MSI was detected in 18.6% of gastric cancers (8 of 43). Neither genome-wide DNA methylation nor MSI had a correlation with *OSR1* promoter methylation (Supplementary Table 5).

*OSR1* methylation is associated with poor survival of gastric cancer patients
------------------------------------------------------------------------------

We further examined the prognostic factors of gastric cancer patients. From the results of univariate Cox regression analysis, *OSR1* methylation was found to be associated with a significant increased risk of cancer-related death. The relative risk (RR) was 2.32, with 95% confidence interval (CI) ranging from 1.45 to 3.70 (*p* \< 0.01). TNM stage was also a significant predictor of outcome as expected. After the adjustment for potential confounding factors, multivariate Cox regression analysis showed that *OSR1* methylation was an independent predictor of poorer survival of gastric cancer patients (RR 1.70, 95% CI 1.04--2.80; *p* \< 0.05). TNM stage was another independent predictor, and patients in TNM stages I--III had a significantly better survival compared with patients in stage IV (Table[1](#tbl1){ref-type="table"}).

###### 

Univariate and multivariate Cox regression analyses of prognostic factors in gastric cancer patients

                       Univariate          Multivariate                       
  -------------------- ------------------- -------------- ------------------- ---------
  Age                  1.00 (0.98--1.02)   0.75           1.01 (0.99--1.02)   0.53
  Gender                                                                      
  Male                 0.99 (0.63--1.55)   0.97           0.91 (0.57--1.44)   0.68
  Female               1.00                               1.00                
  *H. pylori*                                                                 
  Positive             1.05 (0.56--1.97)   0.88                               
  Negative             1.00                                                   
  Lauren                                                                      
  Intestinal           0.67 (0.38--1.18)   0.17                               
  Diffuse/mixed        1.00                                                   
  Differentiation                                                             
  Poor                 1.24 (0.72--2.13)   0.44                               
  Moderate/well        1.00                                                   
  TNM stage                                                                   
  I                    0.09 (0.03--0.28)   \< 0.01        0.10 (0.03--0.31)   \< 0.01
  II                   0.15 (0.07--0.32)   \< 0.01        0.16 (0.07--0.34)   \< 0.01
  III                  0.26 (0.15--0.45)   \< 0.01        0.29 (0.16--0.50)   \< 0.01
  IV                   1.00                               1                   
  *OSR1* methylation                                                          
  Methylated           2.32 (1.45--3.70)   \< 0.01        1.70 (1.04--2.80)   0.04
  Unmethylated         1.00                               1.00                

RR = relative risk; CI = confidence interval.

Kaplan--Meier survival curves showed that gastric cancer patients with *OSR1* methylation had a significantly poorer overall survival than patients without methylation based on the log-rank test (*p* \< 0.01; [Figure 7](#fig07){ref-type="fig"}A). Patients with *OSR1* methylation in TNM stages I--III showed a significantly poorer survival than patients without methylation (*p* \< 0.05; [Figure 7](#fig07){ref-type="fig"}B), but patients in TNM stage IV did not differ significantly (*p* = 0.56; [Figure 7](#fig07){ref-type="fig"}C).

![*OSR1* methylation is associated with poor survival of patients at the early stage of gastric cancer. (A) Kaplan--Meier curves of gastric cancer patients. (B) Kaplan--Meier curves of gastric cancer patients in tumour--nodes--metastasis (TNM) stages I--III. (C) Kaplan--Meier curves of gastric cancer patients in TNM stage IV.](path0234-0302-f7){#fig07}

Discussion
==========

In this study, we demonstrated that *OSR1* was frequently silenced or down-regulated in gastric cancer cell lines. In addition, we found that *OSR1* was also significantly down-regulated at both mRNA and protein levels in primary gastric cancer tissues compared with their adjacent normal tissues. The silencing or down-regulation of *OSR1* was closely associated with promoter hypermethylation, as confirmed by treatment with the demethylating agent 5-Aza and methylation analysis by BGS and MSP, inferring that promoter methylation was the principal regulatory mechanism of *OSR1* inactivation in gastric cancer. There were low levels of methylated gastric cancer cell lines with silencing or down-regulation of *OSR1* expression. We demonstrated that another transcription regulating mechanism such as histone modification also contributed to the gene silencing in these cell lines.

Down-regulation of *OSR1* in gastric cancer suggested that *OSR1* could function as a potential tumour suppressor. We therefore investigated the biological functions of *OSR1* by gain and loss of *OSR1* in human gastric cancer cells. Overexpression of *OSR1* significantly inhibited cell growth in the gastric cancer cell lines AGS, MKN28, and MGC803. Conversely, knockdown of *OSR1* significantly enhanced cell growth in GES1. Flow cytometry analysis showed that *OSR1* induced cell cycle arrest at the G~1~ phase and apoptosis in AGS and GES1. On the other hand, *OSR1* induced cell cycle arrest at the G~2~ phase and apoptosis in MKN28 and MGC803. The tumour suppressive mechanism in AGS and GES1 was likely to be different in MKN28 and MGC803. Collectively, these observations indicate for the first time that *OSR1* functions as a novel tumour suppressor in gastric cancer.

We investigated the signalling pathways by dual-luciferase reporter assay. *OSR1* showed a tumour suppressive effect through the transcriptional activation of p53 in the p53-wild type cell lines AGS, MKN45, and GES1, and through the transcriptional repression of TCF in MKN28 and MGC803. *OSR1* did not repress TCF luciferase reporter activity in AGS, and we confirmed that it was due to the β-catenin mutation in AGS. This mutation may make the Wnt/β-catenin signalling pathway constitutively active, and AGS cells are independent of upstream Wnt signals [@b24]. Therefore, overexpression of *OSR1* could not repress TCF luciferase reporter activity in AGS.

We also studied the molecular mechanisms by which *OSR1* exerted tumour suppressive activity in gastric cancer using the cDNA expression array and western blotting. We found that *OSR1* stabilized p53 in the nucleus, enhanced p21, suppressed cyclin D1 and CDK4 which drove the G~1~ to S phase transition, and stimulated Fas and DR5 receptors, which in turn induced apoptosis through caspase-3 [@b25]--[@b29]. We also found that *OSR1* suppressed the expression of LRP6, cytoplasmic β-catenin, TCF-1, LEF1, and Axin2 in the Wnt/β-catenin signalling pathway. Cytoplasmic β-catenin is considered to separate the centrosome for spindle formation in mitosis [@b30],[@b31]. The level of cytoplasmic β-catenin and TCF transcriptional activity was the highest at the G~2~/M phase as was the peak of cyclin B1, which drives the G~2~ to M phase transition [@b32]--[@b34]. In addition, Axin2 reaches a peak at the G~2~/M phase and provides negative feedback to oscillate the β-catenin levels [@b35]--[@b37]. Therefore, the components of the Wnt/β-catenin signalling may play a crucial role during mitosis.

Although promoter hypermethylation of CpG islands leads to the inactivation of tumour suppressor genes, global DNA hypomethylation is often found in cancers simultaneously [@b38]. We found that *OSR1* promoter methylation occurred independently of global DNA methylation and MSI status. We further evaluated the clinical significance and prognostic value of *OSR1* promoter methylation in primary gastric cancer patients who had known survival data. In multivariate Cox regression survival analysis, *OSR1* methylation was significantly correlated with a shorter survival, independent of other clinicopathological features. This means that *OSR1* promoter methylation can be an independent prognostic marker for gastric cancer patients. As the TNM stage is a highly important predictor of disease recurrence, we used Kaplan--Meier curves stratified by both methylation status and TNM stage. The results showed that *OSR1* methylation was significantly associated with shorter survival for TNM stage I--III gastric cancer patients. This result implies that the propensity for *OSR1* promoter methylation may specifically predict the most aggressive and fatal types of gastric cancer at an early stage.

In conclusion, we suggest that *OSR1* is a novel tumour suppressor gene commonly silenced or down-regulated by promoter methylation in gastric cancer. *OSR1* shows the tumour suppressive function of inhibiting cell growth, arresting the cell cycle, and inducing apoptosis through the transcriptional activation of p53 and the transcriptional repression of TCF/LEF. *OSR1* methylation is an independent predictor of poor survival of patients at the early stage of gastric cancer.
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